# The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer

> **NCT06235164** · — · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 585 (actual)

## Conditions studied

- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab

## Key facts

- **NCT ID:** NCT06235164
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235164, "The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06235164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*